Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma

Fibroblast Growth Factor 21 is independently associated with severe hepatic steatosis in non‐obese HIV ‐infected patients

(2019) Michael Praktiknjo et al.   LIVER INTERNATIONAL

NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis

(2019) Stephen A. Harrison et al.   HEPATOLOGY

Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR–MAPK cascades

(2019) Taisuke Hoshi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

FGF19–FGFR4 Signaling in Hepatocellular Carcinoma

(2019) Aroosha Raja et al.   Cells

Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children?

(2019) Marta Flisiak-Jackiewicz et al.   Advances in Medical Sciences

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma

(2019) Richard D Kim et al.   Cancer Discovery

Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma

(2019) Takahiro Maeda et al.   BMC CANCER

Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice

(2019) Cuiqing Zhao et al.   Molecular Metabolism

Including Fibroblast Growth Factor-21 in Combined Biomarker Panels Improves Predictions of Liver Steatosis Severity in Children

(2019) Man-Chin Hua et al.   Frontiers in Pediatrics

Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice

(2019) Qi Liu et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial

(2018) Dana Friedrich et al.   BMC GASTROENTEROLOGY

A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway

(2018) Lichen Bao et al.   BRITISH JOURNAL OF PHARMACOLOGY

The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients

(2018) Xingxing He et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

(2018) Zobair M. Younossi et al.   Clinics in Liver Disease

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

(2018) Zobair M. Younossi et al.   HEPATOLOGY

Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver

(2018) Guozhen Cui et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

BMS-986036, a PEGylated fibroblast growth factor 21 analogue, reduces fibrosis and Pro-C3 in a mouse model of non-alcoholic steatohepatitis

(2018) Y. Luo et al.   JOURNAL OF HEPATOLOGY

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2018) Stephen A Harrison et al.   LANCET

Mechanisms of NAFLD development and therapeutic strategies

(2018) Scott L. Friedman et al.   NATURE MEDICINE

Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced ALT Elevation

(2018) Heiko S Schadt et al.   TOXICOLOGICAL SCIENCES

Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet

(2018) Garima Singhal et al.   Molecular Metabolism

Physiological Actions of Fibroblast Growth Factor-23

(2018) Reinhold G. Erben   Frontiers in Endocrinology

Effect of hesperidin treatment on α-Klotho/FGF-23 pathway in rats with experimentally-induced diabetes

(2018) Eda Dokumacioglu et al.   BIOMEDICINE & PHARMACOTHERAPY

Oral Abstracts (Abstracts 1-299)

(2018)   HEPATOLOGY

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis

(2018) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

(2018) Arun Sanyal et al.   LANCET

Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

(2018) Edgar D. Charles et al.   Obesity

Chronic consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats

(2017) Sugeedha Jeyapal et al.   EUROPEAN JOURNAL OF NUTRITION

Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration

(2017) Gloria Alvarez-Sola et al.   GUT

Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD

(2017) Na Jiao et al.   GUT

Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD

(2017) Valerio Nobili et al.   LIVER INTERNATIONAL

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease

(2017) et al.   Nutrients

Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

(2017) Lei He et al.   Biomed Research International

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

(2017) et al.   JAMA Oncology

Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD)

(2016) Salamah Mohammad Alwahsh et al.   ARCHIVES OF TOXICOLOGY

Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice

(2016) Bobae Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The FGF21–adiponectin axis in controlling energy and vascular homeostasis

(2016) Xiaoyan Hui et al.   Journal of Molecular Cell Biology

Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma

(2016) Yan Li et al.   Oncotarget

Activation and increase of radio-sensitive CD11b+ recruited Kupffer cells/macrophages in diet-induced steatohepatitis in FGF5 deficient mice

(2016) Hiroyuki Nakashima et al.   Scientific Reports

Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors

(2016) Justin D. Schumacher et al.   Biomed Research International

Fibroblast Growth Factor Signaling in Metabolic Regulation

(2016) Vera J. M. Nies et al.   Frontiers in Endocrinology

Metabolic roles of endocrine fibroblast growth factors

(2015) Isabel Fernandes-Freitas et al.   CURRENT OPINION IN PHARMACOLOGY

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

(2015) Arun J. Sanyal et al.   HEPATOLOGY

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2 -deficient mice

(2015) Mei Zhou et al.   HEPATOLOGY

Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity

(2015) J.-C. Jo et al.   MOLECULAR CANCER THERAPEUTICS

Tissue-based map of the human proteome

(2015) M. Uhlen et al.   SCIENCE

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

(2015) M. Hagel et al.   Cancer Discovery

The Fibroblast Growth Factor signaling pathway

(2015) David M. Ornitz et al.   Wiley Interdisciplinary Reviews-Developmental Biology

Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis

(2015) Mei Yang et al.   PLoS One

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19

(2014) M. Zhou et al.   CANCER RESEARCH

Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?

(2014) Christine Heinzle et al.   CURRENT PHARMACEUTICAL DESIGN

Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment

(2014) Melanie Heroult et al.   Current Signal Transduction Therapy

FGF signaling is required for anterior but not posterior specification of the murine liver bud

(2014) Jikui Wang et al.   DEVELOPMENTAL DYNAMICS

Fibroblast Growth Factor-5 Participates in the Progression of Hepatic Fibrosis

(2014) Hiromi Hanaka et al.   EXPERIMENTAL ANIMALS

Early to Phase II drugs currently under investigation for the treatment of liver fibrosis

(2014) Peter Hauff et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target

(2014) Wen-Yue Liu et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development

(2014) Iker Uriarte et al.   INTERNATIONAL JOURNAL OF CANCER

Lactobacillus rhamnosus GG Protects against Non-Alcoholic Fatty Liver Disease in Mice

(2014) Yvonne Ritze et al.   PLoS One

A nontumorigenic variant of FGF19 treats cholestatic liver diseases

(2014) J. Luo et al.   Science Translational Medicine

Fibroblast growth factor (Fgf) 21 is a novel target gene of the aryl hydrocarbon receptor (AhR)

(2014) Xingguo Cheng et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice

(2013) Zhuofeng Lin et al.   Cell Metabolism

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

(2013) K. M. Habegger et al.   DIABETES

FGF7 is a functional niche signal required for stimulation of adult liver progenitor cells that support liver regeneration

(2013) H. M. Takase et al.   GENES & DEVELOPMENT

Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice

(2013) Iker Uriarte et al.   GUT

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

(2013) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches

(2013) Detlef Schuppan et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

FGF21 regulates metabolism and circadian behavior by acting on the nervous system

(2013) Angie L Bookout et al.   NATURE MEDICINE

βKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism

(2012) Xunshan Ding et al.   Cell Metabolism

Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease

(2012) Fatih Eren et al.   CLINICAL BIOCHEMISTRY

Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis

(2012) Christopher Savard et al.   HEPATOLOGY

A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents

(2012) Malgorzata Wojcik et al.   JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM

Targeting Fibroblast Growth Factor Receptor Signaling in Hepatocellular Carcinoma

(2012) Ann-Lii Cheng et al.   ONCOLOGY

Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

(2012) Dorothy M. French et al.   PLoS One

The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue

(2012) Andrew C. Adams et al.   Molecular Metabolism

Pathogenesis of Liver Fibrosis

(2011) Virginia Hernandez-Gea et al.   Annual Review of Pathology-Mechanisms of Disease

Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease

(2011) Qiang Chen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis

(2011) S. Kir et al.   SCIENCE

The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance

(2010) Tim C. M. A. Schreuder et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease

(2010) Yusuf Yilmaz et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease

(2010) Jody Dushay et al.   GASTROENTEROLOGY

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

(2010) Brent A. Neuschwander-Tetri   HEPATOLOGY

Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis

(2010) Christine Gauglhofer et al.   HEPATOLOGY

FGFs and metabolism

(2009) Alexei Kharitonenkov   CURRENT OPINION IN PHARMACOLOGY

Fibroblast Growth Factor 21 Regulates Lipolysis in White Adipose Tissue But Is Not Required for Ketogenesis and Triglyceride Clearance in Liver

(2009) Yuhei Hotta et al.   ENDOCRINOLOGY

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans

(2008) X. Zhang et al.   DIABETES

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

(2008) J. Xu et al.   DIABETES

Direct Binding of Integrin αvβ3 to FGF1 Plays a Role in FGF1 Signaling

(2008) Seiji Mori et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention

(2008) Han Kiat Ho et al.   JOURNAL OF HEPATOLOGY

Liver cirrhosis

(2008) Detlef Schuppan et al.   LANCET

The Klotho gene family as a regulator of endocrine fibroblast growth factors

(2008) Hiroshi Kurosu et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE